Anemia
Commentary
A new era of TTP treatment
Many questions remain following the FDA’s approval of caplacizumab, specifically, which patients should receive it. The high cost of the drug is...
From the Journals
Single-dose tafenoquine appears to prevent malaria relapse
The drug cut relapse rates in select patients without causing symptomatic anemia.
Clinical Review
Aplastic Anemia: Current Treatment
From the Journals
Matched transplant improves stroke risk indicator in sickle cell anemia
Matched sibling donor hematopoietic stem cell transplants reduced an indicator of stroke risk, suggesting that the intervention may improve...
Clinical Review
Aplastic Anemia: Evaluation and Diagnosis
From the Journals
Plerixafor produced dramatic responses in severe WHIM syndrome
The treatment was effective and well tolerated in patients who could not receive granulocyte colony-stimulating factor therapy.
News
Sickle cell infusion gains FDA breakthrough designation
The investigational therapy is aimed at preventing vasoocclusive crises.
News
Chemo for solid tumors and risk of tMDS/AML
Chemotherapy for solid tumors is associated with an increased risk of therapy-related myelodysplastic syndromes or acute myeloid leukemia (tMDS/...
News
Potential treatment on the horizon for cold agglutinin disease
In a first-in-human trial, sutimlimab rapidly halted hemolysis, corrected anemia, precluded the need for transfusion, and caused no serious...
News
Team reports long-term effects of blood management
An initiative that reduced red blood cell (RBC) transfusions and increased moderate anemia in hospital did not adversely impact patients long-term...
News
FDA approves ravulizumab for PNH
The U.S.